LDCA is a dual-hit metabolic modulator and inhibits LDH-A enzyme activity to stimulate Significantly increased mice survivability combination with doxorubicin, and relieved mice tumor necrosis phenomena.
[1]. Saha, Suchandrima, et al. The dual-hit metabolic modulator LDCA synergistically potentiates doxorubicin to selectively combat cancer-associated hallmarks. RSC Advances, 7(84), 53322-53333. doi:10.1039/c7ra08625c.
















